Get started

Diabetesmed

LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add to the mix of meds and lower their price in the competition may send RHYTHM into launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is considered to be the likely hottest sector of the year. I will look toward OTM call options for February 16th presently priced at about $200 per contract and a couple of shares shorted to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days before upcoming earnings.
NASDAQ:RYTMLong
by AwesomeAvani
1